Health Care

CEO Peetz’s modest Mirum buy‑back and small sales reveal routine insider trading, not market shifts—insightful for investors eyeing future growth.

Insider selling at Relay Therapeutics shows disciplined Rule 10b5‑1 trades amid a 426% YTD rally, hinting at liquidity moves rather than distress.

CEO Souza Marcio’s July 8 sale is a routine portfolio move, not a red flag, as Praxis’s Remagine partnership and 561% annual gain signal strong future upside.

New CFO’s first insider purchase of 50,000 OVID shares signals confidence in the rare‑disorder pipeline and long‑term value. Read the full insights.

Insider trading shows Nuvalent’s CEO buying low, selling high ahead of a potential Harmony Row takeover – a clear liquidity strategy that may cap upside near $124.

Insider buying at AstraZeneca signals confidence – director Sharma Mani’s July purchase hints at a bullish outlook and potential Enhertu gains.

Liquidia insider Stephen Bloch sells 24,000+ shares at $80—investors analyze what it means for stock momentum and future confidence.

Hamilton Thomas Edward’s July 6 insider purchase of 50k Larimar Therapeutics shares signals strong confidence in the rare‑disease pipeline and management, fueling a bullish market trend.

Insider selling trend at Simulations Plus: Chief Revenue Officer DiBella’s recent 1,000‑share sale hints at a cautious portfolio shift amid rising drug‑simulation prospects.

Insider sales at SOPHiA GENETICS show disciplined liquidity planning, not a confidence dip—executive Jurgi’s July 7 trade confirms strong, rising fundamentals.